Section 5 of 6
Economic information and modeling report
24 evidence topics · 17 sources
Modeling overview
Summary: published economic evaluations
No cost-effectiveness analysis, budget impact model, or health technology assessment of obefazimod was identified as of November 2026, and no obefazimod price has been announced. Published U.S. evaluations address the advanced therapies obefazimod would join. The Institute for Clinical and Economic Review (ICER) 2020 review modeled six targeted immune modulators and two biosimilars in moderate-to-severe ulcerative colitis with a Markov model of eight-week cycles, a health care sector perspective, a lifetime horizon, and 3% annual discounting. Cost per QALY ranged from $186,000 (infliximab-dyyb) to $1,870,000 (adalimumab); in the biologic-experienced population, the incremental cost-effectiveness ratio against conventional treatment ranged from $495,000 (tofacitinib) to $1,885,000 (adalimumab). ICER's five-year potential budget impact analysis of ustekinumab estimated that about 21% of eligible patients could be treated at wholesale acquisition cost, and about 51% at estimated net price, without crossing its threshold of approximately $819 million per year.
Bloudek et al. evaluated 21 treatment sequences in the base case and found infliximab or a biosimilar first line optimal by net health benefit and cost minimization. ICER's 2026 special assessment of Entyvio for the Centers for Medicare & Medicaid Services (CMS) used a lifetime Medicare model and found 30-day price premiums for Entyvio over infliximab in ulcerative colitis of $420 to $550 across thresholds of $50,000 to $200,000 per evLY, and no price premium supported over ustekinumab. Gulati et al. estimated cost per remission for mirikizumab and ustekinumab as second-line therapy from a U.S. commercial payer perspective. Shaffer et al. found that continuing 5-aminosalicylate with a biologic or tofacitinib was dominated by monotherapy. A review of 40 cost and health care resource use studies by Cichewicz et al. reported that biologic costs were not always offset by lower disease management costs and that switching and dose escalation increased drug costs. Each of these models is a candidate structure for a plan's obefazimod evaluation, and each would need an obefazimod price, which does not yet exist, and comparative efficacy inputs.
Summary: inputs available and absence of an obefazimod price or model
No budget impact model of obefazimod was identified, and Abivax has published no price. A plan building its own model can draw the eligible population from the U.S. prevalence of ulcerative colitis, 378 per 100,000, or 0.64% of Medicare fee-for-service beneficiaries. No recent peer-reviewed estimate of the moderately to severely active share exists; ICER's 2020 model used 22%, from the Crohn's and Colitis Foundation. Advanced-therapy uptake among patients newly diagnosed with ulcerative colitis in 2019 to 2023 was 27% at 1 year and 38% at 5 years. Abivax estimates about 271,000 U.S. advanced-therapy patients in 2025 and about 300,000 moderate-to-severe patients on conventional therapy or steroids only, and its research names that conventional-therapy group as the population in which physicians would likely start obefazimod.
The obefazimod price figures available are analyst assumptions: LifeSci Capital assumed a U.S. net annual price at launch of US$78,000, increased from US$66,000. Comparator costs available from public sources include ICER's January 2026 Medicare inputs (annual maintenance net cost $39,423 for intravenous vedolizumab, $27,221 for subcutaneous ustekinumab biosimilar, and $5,430 for an intravenous infliximab biosimilar in ulcerative colitis), the Medicare negotiated price for Stelara of $4,695.00 per 30-day supply, and wholesale acquisition costs reported to California for tofacitinib, upadacitinib, ozanimod, etrasimod, risankizumab, mirikizumab, and vedolizumab. Medicare negotiated prices for Entyvio and Xeljanz, selected for negotiation, take effect beginning in 2028. Non-drug inputs (colectomy $33,871 per admission; health-state costs) come from ICER's 2020 model. These inputs differ in date, price basis (list, net, or negotiated), and payer, so a plan would need to align them before use.
Targeted immune modulators versus conventional treatment: ICER U.S. cost-effectiveness model, 2020
Targeted immune modulators versus conventional treatment: peer-reviewed summary of the ICER 2020 model
“We evaluated the cost-effectiveness from the U.S. health care sector perspective of the 6 TIMs and 2 biosimilars over a lifetime time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The average net pricing estimates for TIMs with oral and subcutaneous modes of administration were obtained from SSR Health. For IV-administered TIMs, we used Centers for Medicare & Medicaid Services average sales prices (ASP) plus 9.5%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“cost-effectiveness was closest to $150,000 per quality-adjusted life-year (QALY) for infliximab and its biosimilars: infliximab-dyyb and infliximab-adba ($212,000, $186,000 and $195,000 per QALY, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the biologic-experienced population (Table 2), the incremental cost-effectiveness ratio compared with conventional treatment was highest for adalimumab ($1,885,000) and lowest for tofacitinib ($495,000).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary limitations of our cost-effectiveness analysis included restricted data availability, a paucity of information on treatment sequencing or switching, and our need to base outcomes for conventional treatment solely on the results from the placebo arms of the trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Ustekinumab: ICER U.S. potential budget impact analysis, 2020
| Annualized per-patient budget impact over five years | At list price | At net price | At $150,000/QALY price | At $100,000/QALY price | At $50,000/QALY price |
|---|---|---|---|---|---|
| Ustekinumab | “$73,600” | “$53,100” | “$28,800” | “$27,600” | “$26,400” |
| Market basket (55% biologic-naive, 45% biologic-experienced) | “$37,500” | “$37,500” | “$37,500” | “$37,500” | “$37,500” |
| Net impact | “$36,100” | “$15,600” | “-$8,700” | “-$9,900” | “-$11,100” |
Treatment sequences of targeted immune modulators: U.S. payer cost-effectiveness model
“The model was developed as a Markov model with 8-week cycles over a lifetime time horizon from a US payer perspective, including only direct health care costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Drug costs were updated to reflect prices as of May 2020.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“21 possible sequences were evaluated in the base case.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“None of the sequences had an incremental cost per QALY below $150,000 relative to 2 attempts with conventional treatment, so the resulting NHB was negative for all sequences.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Based on the results of this analysis, the optimal sequence of TIMs as measured by NHB and cost minimization was infliximab or biosimilars as first-line treatment, then moving to tofacitinib, adalimumab, or vedolizumab. Sequences that generated the most QALYs began with ustekinumab, followed by vedolizumab, tofacitinib, and adalimumab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Vedolizumab versus infliximab and ustekinumab: ICER special assessment for Medicare price negotiation, 2026
Mirikizumab versus ustekinumab after biologic or Janus kinase inhibitor exposure: U.S. commercial payer cost per remission model
“An Excel-based analytic model was developed to estimate the cost per additional patient achieving clinical remission at the end of one year in biologic/Janus kinase inhibitor (JAKi)-experienced patients (second-line therapy) with UC from a United States commercial payer perspective.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The model included the treatment cost (wholesale acquisition costs [WAC] and treatment administration costs) during the induction and maintenance phases.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The costs per patient achieving clinical remission for mirikizumab vs. ustekinumab as a second-line therapy were $461,096 vs. $67,273 during induction and $501,456 vs. $1,079,189 during maintenance.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Considering the ustekinumab 130 mg IV biosimilar, the scenario resulted in a lower cost per clinical remission for mirikizumab vs. a ustekinumab biosimilar during the maintenance phase ($501,456 vs. $539,594).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Continuing versus stopping 5-aminosalicylate with a biologic or tofacitinib: U.S. cost-effectiveness model
“Medications are major cost drivers in the treatment of patients with inflammatory bowel disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our model shows that biologic/tofacitinib monotherapy dominates (cheaper and more effective) combination therapy of biologics/tofacitinib with 5-ASA. Probabilistic sensitivity analyses simulations resulted in biologic/tofacitinib monotherapy dominating 100% of the scenarios, with mean cost savings of $24,483.01 over 2 years.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Costs of advanced therapies in moderate-to-severe ulcerative colitis: systematic review of observational studies
“47 publications of 40 unique cost/HCRU studies and 13 publications of nine unique HRQoL studies were included.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“High costs of biologics were not always fully offset by reductions in cost and HCRU associated with disease management. For many patients, treatment switching and dose escalations were required, thus increasing drug costs, particularly when switching across treatment classes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of ulcerative colitis in the United States, pooled commercial, Medicare, and Medicaid claims
“The age-, sex- and insurance-standardized prevalence per 100,000 population was 721 (95% CI 717 – 726) for IBD, 378 per 100,000 (95% CI 375 – 382) for ulcerative colitis and 305 (95% CI 302 – 308) for Crohn’s disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Extrapolated to the 2020 census estimate of 331,449,281 US population, there is an estimated 2.390 million Americans with IBD, 1.253 million with ulcerative colitis and 1.011 million with Crohn’s disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prevalence of ulcerative colitis among Medicare fee-for-service beneficiaries
Share with moderate-to-severe disease activity: ICER 2020 eligible-population estimate
Uptake of advanced therapy after diagnosis among commercially insured U.S. adults
“Cumulative 1- and 5y use of advanced therapy was 17% (95% CI, 15–18) and 29% (95% CI, 27–31), respectively (Table 1). In a more contemporary cohort of patients diagnosed in 2019–23, the corresponding rate was 27% (95% CI, 24–29) and 38% (95% CI, 34–41), respectively (aHR, 3.43 [95% CI, 2.86–4.13]) (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Company estimates of U.S. advanced-therapy use and of moderate-to-severe patients on conventional therapy
Analyst assumption: LifeSci Capital U.S. net annual price at launch, June 2026
Comparator drug costs in the ICER Medicare model, prices of January 2026
| Drug | WAC per dose | Discount from WAC | Primary source | Net price per dose | Annual net cost of maintenance |
|---|---|---|---|---|---|
| Vedolizumab IV (Entyvio) | “Not Applicable” | “Not Applicable” | “ASP” | “$6,048” | “$39,423” |
| Vedolizumab SC (Entyvio) | “$3,639” | “29.23%” | “REDBOOK” | “$2,575” | “$67,145” |
| Infliximab IV (biosimilar) | “Not Applicable” | “Not Applicable” | “ASP” | “$833 (UC)” | “$5,430 (UC)” |
| Infliximab SC (Zymfentra) | “$3,343” | “10%” | “REDBOOK” | “$3,008” | “$78,435” |
| Ustekinumab IV (biosimilar), induction only | “Not Applicable” | “Not Applicable” | “ASP” | “$3,522” | Not applicable |
| Ustekinumab SC (biosimilar) (90 mg) | “$4,176” | “Not Applicable” | “REDBOOK” | “$4,176” | “$27,221” |
Ustekinumab: Medicare negotiated price effective January 2026 and 2023 list price
| Drug | Participating drug company | Agreed to negotiated price for 30-day supply for CY 2026 | List price for 30-day supply, CY 2023 | Discount of negotiated price from 2023 list price |
|---|---|---|---|---|
| Stelara (ustekinumab) | “Janssen Biotech, Inc.” | “$4,695.00” | “$13,836.00” | “66%” |
Vedolizumab and tofacitinib: selection for the third cycle of Medicare price negotiation
| Selected drug | Drug name | Participating manufacturer |
|---|---|---|
| Vedolizumab | “Entyvio” | “Takeda Pharmaceuticals U.S.A., Inc.” |
| Tofacitinib | “Xeljanz; Xeljanz XR” | “PF PRISM CV” |
Wholesale acquisition costs of risankizumab, tofacitinib, and vedolizumab reported to California, 2026
Wholesale acquisition costs of upadacitinib and ozanimod reported to California, January 2025
| Product and package | Manufacturer | Drug product description | WAC effective date | WAC increase amount (USD) | WAC after increase (USD) |
|---|---|---|---|---|---|
| Rinvoq (upadacitinib) 15 mg, 30 tablets | “AbbVie” | “RINVOQ TABLET EXTENDED RELEASE 24 HR 15 mg 30” | “01/02/2025” | “321.56” | “6752.77” |
| Rinvoq (upadacitinib) 30 mg, 30 tablets | “AbbVie” | “RINVOQ TABLET EXTENDED RELEASE 24 HR 30 mg 30” | “01/02/2025” | “321.56” | “6752.77” |
| Rinvoq (upadacitinib) 45 mg, 28 tablets | “AbbVie” | “RINVOQ TABLET EXTENDED RELEASE 24 HR 45 mg 28” | “01/02/2025” | “600.24” | “12605.04” |
| Zeposia (ozanimod) 0.92 mg, 30 capsules | “Bristol Myers Squibb” | “0.92MG CAP 30CT BTL US” | “01/01/2025” | “400.04” | “9289.90” |
Wholesale acquisition costs of etrasimod and mirikizumab at introduction, October 2023
| Product and package | Manufacturer | Drug product description | Date introduced to market | WAC at introduction (USD) |
|---|---|---|---|---|
| Velsipity (etrasimod) 2 mg, 30 tablets | “Pfizer” | “VELSIPITY 2MG TFC 1X30 PBTL US” | “2023-10-19” | “6164.3800” |
| Omvoh (mirikizumab) 300 mg vial | “Eli Lilly and Company” | “OMVOH 20 mg/mL (300 mg/15 mL) 1 300 mg vial” | “2023-10-27” | “9593.2200” |
| Omvoh (mirikizumab) 100 mg/mL, 2 prefilled pens | “Eli Lilly and Company” | “OMVOH 100 mg/mL 2 single patient-use prefilled pens” | “2023-10-27” | “10360.6700” |
Annual wholesale acquisition costs and estimated net prices in the ICER 2020 model, May 2020
Colectomy, serious infection, and health-state costs in the ICER 2020 model
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.